• Nine abstracts showcasing developments across inflammation & neuroinflammation, psychiatric disease, depression & more! We'll be at Booth No.1818.
  • Transpharmation joins HaPpY team to help break the vicious cycle of chronic pain & mood disorders, see News for details
  • Announcing new premises in Poland with a focus on neuropsychiatric disorders...
  • New state-of-the-art premises at Discovery Park, Kent
 

Pain

Transpharmation offers an extensive array of highly behaviourally and pharmacologically validated rodent models of pain. Our services span acute, chronic, inflammatory, osteoarthritic and neuropathic pain conditions with evoked and non-evoked end points, all of which are benchmarked against clinical gold standard compounds.

Our capabilities are wide ranging and include the use of translational technology, such as UV radiation to induce localised inflammation and laser doppler to measure blood flow; plasma/tissue sample collection to establish PK/PD relationships and measure inflammatory biomarkers, and transcriptomic analysis to determine mechanistic aspects of disease progression and predict responders / non-responders to NCE analgesics.

Examples of the models we offer extend to the following:

  • CCI (Bennett) model of neuropathic pain
  • STZ-induced diabetic neuropathy
  • Chemotherapy-induced neuropathy, (Oxaliplatin)
  • CFA / carrageenan / capsaicin / formalin inflammatory pain
  • MIA / CFA osteoarthritis joint pain
  • Acute mechanistic pain models, e.g. NGF
  • Ultraviolet light (UV) burn

Examples of end points:


pain1This list is not exhaustive, we are always developing new areas of discovery within our preclinical field of expertise. If there is something particular that is not listed here please do contact us.

Start a Conversation

preclinical +44 (0)203 633 2807

clinical trials +353 (0)1896 42 60

clinical research +48 515 244 120

EEG contact@transpharmation.co.uk


Copyright ©2021 Transpharmation Ltd. Website created by Identity Ipswich Web Design